In late February 2026, Bristol Myers Squibb and partner SystImmune reported that antibody-drug conjugate izalontamab brengitecan (iza-bren) achieved statistically significant, clinically meaningful ...
A Chinese phase 3 trial of Bristol Myers Squibb’s antibody-drug conjugate has hit its dual primary survival endpoints, ...
The S&P 500 index ( ^GSPC 0.43%) is offering a tiny 1.1% dividend yield today. The average pharmaceutical stock yields around 1.7%. Bristol Myers Squibb ( BMY +1.87%), however, is offering investors a ...
Global pharmaceutical giant Bristol Myers Squibb is laying off more New Jersey employees as part of an ongoing cost-cutting ...
The pharma industry's dreaded patent cliff is a key driver of the stock's decline.
Bristol-Myers Squibb Company is rated a Strong Buy as its growth portfolio now accounts for nearly 60% of total revenue. Read ...
Bristol-Myers Squibb & Co. BMY on Monday released topline results from a phase 2 study evaluating Reblozyl for anemia in ...
Bristol Myers Squibb is part of the biopharmaceutical sector, a segment defined by research driven drug development, global ...
FDA accepts Bristol Myers Squibb’s New Drug Application for iberdomide in relapsed or refractory multiple myeloma. The filing ...
Financial giants have made a conspicuous bullish move on Bristol-Myers Squibb. Our analysis of options history for Bristol-Myers Squibb (NYSE:BMY) revealed 9 unusual trades. Delving into the details, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results